A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
about
Progress towards gene therapy for cystic fibrosisGene therapy in clinical medicineAdeno-associated virus for cystic fibrosis gene therapyAdeno-associated virus: from defective virus to effective vectorBarriers to inhaled gene therapy of obstructive lung diseases: A reviewEvaluation of a Serum-free Medium for the Production of rAAV-2 using HeLa Derived Producer CellsAAV's anatomy: roadmap for optimizing vectors for translational successTransduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro.Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses.Chromosomal integration and homologous gene targeting by replication-incompetent vectors based on the autonomous parvovirus minute virus of mice.Adeno-associated virus-mediated gene transferHigh-efficiency transduction of fibroblasts and mesenchymal stem cells by tyrosine-mutant AAV2 vectors for their potential use in cellular therapyEfficient generation and amplification of high-capacity adeno-associated virus/adenovirus hybrid vectors.A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transductionPseudotyped AAV vector-mediated gene transfer in a human fetal trachea xenograft model: implications for in utero gene therapy for cystic fibrosis.AAV2-mediated in vivo immune gene therapy of solid tumours.A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.Gene therapy using adeno-associated virus vectorsCurrent status of gene therapy for inherited lung diseasesImmunological hurdles to lung gene therapy.Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia.Safety of adeno-associated virus gene therapy vectors: a current evaluation.Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.Unique biologic properties of recombinant AAV1 transduction in polarized human airway epithelia.Advances in AAV-mediated gene transfer for the treatment of inherited disorders.Gene therapy in orthopaedic surgery: the current status.Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors.Optimization of Recombinant Adeno-Associated Virus-Mediated Expression for Large Transgenes, Using a Synthetic Promoter and Tandem Array EnhancersGene therapy for cystic fibrosis: an example for lung gene therapy.Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90Novel molecular approaches to cystic fibrosis gene therapy.Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airwayDistinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epitheliaRapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors.Gene therapy for the treatment of cystic fibrosis.Strategies for manufacturing recombinant adeno-associated virus vectors for gene therapy applications exploiting baculovirus technology.Lentivirus vector can be readministered to nasal epithelia without blocking immune responsesThe state of the art of adeno-associated virus-based vectors in gene therapy.Postentry processing of recombinant adeno-associated virus type 1 and transduction of the ferret lung are altered by a factor in airway secretions.CFTR gene transfer with AAV improves early cystic fibrosis pig phenotypes
P2860
Q22306014-6058DF57-D3E5-4179-83BC-4C11668D47C1Q24680275-3D626021-73F7-4CC8-ACAF-DEEBC4A6C8E3Q26823156-03732B7E-21EC-4DF8-B869-71F5569020BAQ27498163-2E474A8D-02DB-49B2-935B-6D5F1B86B93CQ29248141-F2D42141-F745-4034-AB29-E3D1FBF177D4Q30462040-6A6B0A6B-4C6C-4034-9C0D-4331DFAAE201Q33659389-7E76E247-729E-4889-BCDD-07FB630DD095Q33713277-D933341A-C329-4DAE-94A9-1F14D72C09C0Q33832799-B68E889B-CDDB-4B32-B310-FD9B89ED6E32Q34226663-81B1C54D-D9ED-4691-98E3-17663818D9FCQ34317131-C4A66145-B057-48D3-8917-F6039B0E8B80Q34329364-B0CC6FE7-4F3A-441F-9728-D28EEFA40F07Q34349393-B0ED9C32-30D6-48C1-ACB3-557C123CECC1Q34356203-4374CE65-F968-4ECD-925B-7071DAE98AF9Q34399258-B9CDEE6A-650F-47CF-AB93-08DE09C12C49Q34468330-83280E40-7329-49DC-B29B-A154C696824CQ34843762-F3D685D5-8955-410F-9C9B-57E7523922D6Q34852719-76B55AAA-8CED-4592-9B8A-924C9E043E8FQ35043830-7232F9C9-BAC1-479D-BE53-C14B4636BD31Q35091006-35ED6172-84A9-4928-8B48-2E1BD73B3A11Q35150199-AD7FE4A1-0EB3-4BD2-92F1-E9F40696E1B3Q35194547-4AFD5E00-8AB0-4806-8F41-4D583BA9A32BQ35200182-1BD6214C-6CEB-4B11-9A50-9B76FAB75191Q35239472-75468CFA-49B6-4A9E-986C-DEDC9631F210Q35628533-5066BFB3-8C62-4534-AE09-AFB13EF4D968Q35630146-60C76F11-B8FC-41D3-9BAE-399CF6D7668EQ35712206-70282964-5114-47C9-8BB3-C40C0D871442Q35821858-6F99E958-1A5B-43E2-80CB-EAB6B2337F46Q35904424-89B72980-84C6-4B7B-96C1-4AC4BD165115Q36004744-DF9558B2-6469-4299-91AF-8327672E0E21Q36012920-4DC41C6F-860D-42E5-9652-88798D92AE71Q36315561-9CED5330-7D85-4ACE-B2A8-B5644859587BQ36509719-3A9CF45B-5E58-4FC3-8152-AAB162FDEA8FQ36509889-6446DD11-C97D-47AE-8A8C-4E40D44B26A7Q36925241-701E3E00-BA06-44E4-BA96-351EE78C6150Q36925619-D6EDE8AE-862B-492B-B1ED-D430E1ACF3CCQ36949698-AC87A9AD-A1F5-4ED1-82B9-18DD43B3CE10Q36972714-D08DB139-767E-46D9-8B95-A65824C72F64Q37158813-674BF875-F21A-4ADA-9CC1-4DCFCCAA9ECCQ37277305-32138984-6C15-43C2-9B1F-ADD95067A20A
P2860
A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
A phase I study of aerosolized ...... bjects with mild lung disease.
@en
A phase I study of aerosolized ...... bjects with mild lung disease.
@nl
type
label
A phase I study of aerosolized ...... bjects with mild lung disease.
@en
A phase I study of aerosolized ...... bjects with mild lung disease.
@nl
prefLabel
A phase I study of aerosolized ...... bjects with mild lung disease.
@en
A phase I study of aerosolized ...... bjects with mild lung disease.
@nl
P2093
P1433
P1476
A phase I study of aerosolized ...... bjects with mild lung disease.
@en
P2093
McNamara SC
Reynolds TC
Tonelli MR
P304
P356
10.1089/104303401753153956
P577
2001-10-01T00:00:00Z